Furthermore, up to 20% of relapsed neuroblastoma cases may acquire druggable ALK mutations [31], which is another good reason to pursue tissue procurement every time the disease progresses or recurs in order to better accomplish rescue treatment strategies. The gene discussed is ALK; the disease is neuroblastoma.